Traders purchased shares of Eli Lilly And Co (NYSE:LLY) on weakness during trading on Thursday following insider selling activity. $180.20 million flowed into the stock on the tick-up and $98.34 million flowed out of the stock on the tick-down, for a money net flow of $81.86 million into the stock. Of all equities tracked, Eli Lilly And Co had the 23rd highest net in-flow for the day. Eli Lilly And Co traded down ($0.68) for the day and closed at $115.84Specifically, major shareholder Eli & Co Lilly sold 10,059 shares of the company’s stock in a transaction dated Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total value of $149,174.97. Following the transaction, the insider now owns 3,894,318 shares of the company’s stock, valued at $57,752,735.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 15,500 shares of the company’s stock in a transaction dated Tuesday, December 4th. The shares were sold at an average price of $119.00, for a total transaction of $1,844,500.00. Following the completion of the transaction, the insider now directly owns 118,015,304 shares in the company, valued at approximately $14,043,821,176. The disclosure for this sale can be found here. Insiders have sold 2,142,800 shares of company stock valued at $168,818,353 in the last ninety days. Insiders own 0.11% of the company’s stock.

A number of research analysts have commented on the stock. Zacks Investment Research raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research report on Wednesday. Citigroup cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 target price on the stock. in a research report on Sunday. ValuEngine raised shares of Eli Lilly And Co from a “hold” rating to a “buy” rating in a research report on Monday, November 12th. TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a research report on Tuesday, November 6th. Finally, Societe Generale set a $106.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Wednesday, November 7th. Nine research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $111.53.

The stock has a market capitalization of $123.43 billion, a PE ratio of 27.07, a PEG ratio of 1.82 and a beta of 0.31. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.35 by $0.04. The business had revenue of $6.06 billion for the quarter, compared to analysts’ expectations of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The business’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.05 earnings per share. Research analysts anticipate that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, November 14th. This represents a $2.25 annualized dividend and a dividend yield of 1.94%. Eli Lilly And Co’s dividend payout ratio is presently 52.57%.

Institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC increased its stake in shares of Eli Lilly And Co by 526.5% during the third quarter. FMR LLC now owns 7,444,216 shares of the company’s stock worth $798,838,000 after buying an additional 6,255,915 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Eli Lilly And Co by 54.0% during the third quarter. TIAA CREF Investment Management LLC now owns 4,693,492 shares of the company’s stock worth $503,659,000 after buying an additional 1,644,879 shares during the period. Morgan Stanley increased its stake in shares of Eli Lilly And Co by 37.8% during the second quarter. Morgan Stanley now owns 4,473,537 shares of the company’s stock worth $381,727,000 after buying an additional 1,227,888 shares during the period. AQR Capital Management LLC increased its stake in shares of Eli Lilly And Co by 89.2% during the third quarter. AQR Capital Management LLC now owns 2,018,685 shares of the company’s stock worth $216,625,000 after buying an additional 951,817 shares during the period. Finally, BlackRock Inc. increased its stake in shares of Eli Lilly And Co by 1.3% during the second quarter. BlackRock Inc. now owns 66,644,897 shares of the company’s stock worth $5,686,808,000 after buying an additional 864,451 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Traders Buy Shares of Eli Lilly And Co (LLY) on Weakness After Insider Selling” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.watchlistnews.com/traders-buy-shares-of-eli-lilly-and-co-lly-on-weakness-after-insider-selling/2665706.html.

Eli Lilly And Co Company Profile (NYSE:LLY)

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: What type of investment options does a Roth IRA provide?

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.